Rising to the challenges of rare disease treatment
We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Specialized BioTherapeutics Pipeline
Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|---|---|---|---|
| SGX301 for Cutaneous T-Cell Lymphoma (CTCL) | ||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
Market
|
| SGX942 for Oral Mucositis | ||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
Market
|
| SGX203 for Pediatric Crohn’s Disease | ||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
Market
|
| SGX201 for Radiation Enteritis | ||||
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
Market
|
Orphan and/or Fast Track Designation
Denotes funding in whole or in part by NIH, BARDA and/or FDA.
Public Health Solutions Pipeline
Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.
| Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
|---|---|---|---|---|
| RiVax® to Prevent Ricin Poisoning | ||||
|
Proof-of-Concept
|
IND
|
Phase 1
|
Phase 2/3
|
Market
|
| OrbeShield® for Acute Radiation Syndrome | ||||
|
Proof-of-Concept
|
IND
|
Phase 1
|
Phase 2/3
|
Market
|
| SGX943 for Infectious Disease | ||||
|
Proof-of-Concept
|
IND
|
Phase 1
|
Phase 2/3
|
Market
|
Orphan and/or Fast Track Designation
Denotes funding in whole or in part by NIH, BARDA and/or FDA.
The Latest
Resources
News
External Link
Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide
Ebola: Chisholm F, Kang JT, Dong M, Lewis K, Namekar M, Lehrer AT, Randolph TW. Thermostable Ebola Virus Vaccine Formulations Lyophilized in the Presence of Aluminum Hydroxide. Eur. J. Pharm. Bipharm. 2019. 136: 213-20.
External Link
Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…